United Kingdom (UK)
Recombinant monoclonal antibody to haloperidol. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma Clone A.
Alternative Name(s) of Target: Haldol; 185(2)-1; A; Einalon S; Eukystol; Aloperidin; Bioperidolo; Brotopon; Dozic; Duraperidol; Halosten; Keselan; Linton; Peluces; Serenace; Sigaperidol
Immunogen: This antibody was raised against a haloperidol-BSA conjugate in which the drug was linked to the protein carrier via a succinic acid linker arm through the tertiary alcohol function on the piperidine ring (succinic acid conjugate).
Specificity: Thi antibody recognises haloperidol which is one of the major antipsychotic drugs. It is a D2 dopamine receptor antagonist and is widely used in treatment of schizophrenia, psychosis and mania. Antibody A prefers a folded confirmation of haloperidol and binds to a different site on the molecule than anti-haloperidol antibody D.
Application Notes: RIA: radioligand binding assays were performed to asses binding affinity of the anti-haloperidol A antibody (Kd=3.3 nM). (Sherman et al., 1986).
Antibody first published in:
Bolger et al. Preparation and characterization of antisera and monoclonal antibodies to haloperidol. Immunol Invest. 1985 Dec;14(6):523-40. PMID:2420719
Note on publication:
This article describes the preparation of the monoclonal antibodies which specifically bind haloperidol, among them this 258(2)-i antibody (later renamed as anti-haloperidol antibody D).